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In June 2013, the Journal of the American
Academy of Dermatology published a report con-
cerning successful treatment of 2 cases of alopecia
totalis with hydroxychloroquine.1 This report was
encouraging, as treatment of alopecia totalis is
challenging and in most cases unsuccessful. The
authors explained their results with the wide range
of immunomodulatory effects that are attributed
to hydroxychloroquine.2 These effects include
decreased secretion of proinflammatory cytokines
and reduced production of lymphocytes and
autoantibodies.3 As a consequence of their results,
we investigated hydroxychloroquine treatment for
extensive alopecia in a larger cohort.METHODS
Eight patients (6 women, 2 men) with a mean age
of 30.2 years (range, 16e53) were treated with
hydroxychloroquine during 2013 and 2014. Six
patients suffered from alopecia totalis, whereas 2
patients had extensive alopecia areata that involved
more than 40% of the scalp. Mean duration of the
disease was 3.9 years (range, 1e8), and all patients
had previously tried various treatments such as
topical/intralesional corticosteroids, contact immu-
notherapy, and ultraviolet therapy without effect. No
patients were treated with oral steroids.
Before hydroxychloroquine treatment, patients
were screened for retinopathy by an ophthalmolo-
gist, and a complete blood count was performed.
Patients were prescribed 200 mg hydroxychloro-
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function were done monthly. Because it takes about
2 months for hydroxychloroquine to work, patients
were followed up after 3 to 4 months, and treatment
was stopped if there was no sign of regrowth. In the
case of regrowth, treatment was prolonged but was
discontinued if the condition relapsed. Informed
consent was obtained from all patients before
treatment start.RESULTS
All patients were treated with hydroxychloro-
quine for at least 101 days (mean, 161; range,
101e300 days). At follow-up, 5 patients discontin-
ued treatment because of lack of regrowth;
whereas 3 patients continued hydroxychloroquine.
Two patients with alopecia totalis showed minimal
signs of regrowth, but relapse ensued, and hydrox-
ychloroquine was discontinued after 148 and
197 days of treatment, respectively (Fig 1). Our
last patient had extensive alopecia areata and
experienced widespread regrowth. However,
despite continuing to take the full hydroxychlor-
oquine dose, she suddenly suffered relapse. Thus,
we concluded that her regrowth was of sponta-
neous origin, and hydroxychloroquine was discon-
tinued after 300 days.
Four patients reported intermittent gastrointestinal
discomfort as a side effect to hydroxychloroquine, but
none discontinued treatment as a result. One patient
experienced blurred vision during treatment, but
ophthalmologists found no sign of retinopathy, and
the patient continued hydroxychloroquine.JAAD Case Reports 2016;2:117-8.
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Fig 1. Alopecia totalis in a 22-year-old woman. A, Baseline photography before study start. B,
Minimal regrowth after 4 months of hydroxychloroquine treatment. Treatment was discon-
tinued shortly after because of relapse.
JAAD CASE REPORTS
MARCH 2016
118 Nissen and WulfDISCUSSION
Extensive alopecia is a condition that often puts
the physician in a dilemma. On one hand, patients
are desperately seeking an effective treatment. On
the other hand, the commonly used treatments
rarely prove successful and cause a number of
side effects.4 With a lack of randomized, placebo-
controlled studies, physicians are often led to
engage in treatments that are not evidence based.5
Our study illustrates this problem, as our investiga-
tion was not randomized or placebo controlled.
Although our study design was not ideal, we still
believe that our results are important. As re-
searchers we are obligated to publish negative
results to ensure that our colleagues and patients
do not engage in time-consuming treatments
that are likely to be fruitless. We based this
investigation on a case report in which hydroxy-
chloroquine had remarkable effect on treatment-
resistant alopecia totalis and wished to investigate
this in a similar patient population. Because none of
our 8 patients experienced lasting regrowth, wecannot recommend hydroxychloroquine as treat-
ment for extensive alopecia where other treatment
modalities have failed. Taking side effects and our
discouraging results further into account, it is
questionable whether it is feasible to initiate a
placebo-controlled trial.REFERENCES
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